Search

Your search keyword '"Esteban-De Antonio, Ester"' showing total 19 results
Start Over Author "Esteban-De Antonio, Ester"
19 results on '"Esteban-De Antonio, Ester"'

1. Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

Author

Cano, Amanda, Esteban-de-Antonio, Ester, Bernuz, Mireia, Puerta, Raquel, García-González, Pablo, de Rojas, Itziar, Olivé, Claudia, Pérez-Cordón, Alba, Montrreal, Laura, Núñez-Llaves, Raúl, Sotolongo-Grau, Óscar, Alarcón-Martín, Emilio, Valero, Sergi, Alegret, Montserrat, Martín, Elvira, Martino-Adami, Pamela V., Ettcheto, Miren, Camins, Antonio, Vivas, Assumpta, Gomez-Chiari, Marta, Tejero, Miguel Ángel, Orellana, Adelina, Tárraga, Lluís, Marquié, Marta, Ramírez, Alfredo, Martí, Mercè, Pividori, María Isabel, Boada, Mercè, and Ruíz, Agustín

Published
2023
Full Text
View/download PDF

2. Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort

Author

García-Sánchez, Ainhoa, Sotolongo-Grau, Oscar, Tartari, Juan Pablo, Sanabria, Ángela, Esteban - De Antonio, Ester, Pérez-Cordón, Alba, Alegret, Montserrat, Pytel, Vanesa, Martínez, Joan, Aguilera, Núria, de Rojas, Itziar, Cano, Amanda, García-González, Pablo, Puerta, Raquel, Olivé, Clàudia, Capdevila, Maria, García-Gutiérrez, Fernando, Vivas, Assumpta, Gómez-Chiari, Marta, Giménez, Juan, Tejero, Miguel Ángel, Castilla-Martí, Miguel, Castilla-Martí, Luis, Tárraga, Lluís, Valero, Sergi, Ruiz, Agustín, Boada, Mercè, and Marquié, Marta

Published
2024
Full Text
View/download PDF

3. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort

Author

Marquié, Marta, Valero, Sergi, Martínez, Joan, Alarcón-Martín, Emilio, García-Sánchez, Ainhoa, de Rojas, Itziar, Castilla-Martí, Miguel, Castilla-Martí, Luis, Hernández, Isabel, Rosende-Roca, Maitée, Vargas, Liliana, Tartari, Juan Pablo, Esteban-De Antonio, Ester, Bojaryn, Urszula, Pytel, Vanesa, Narvaiza, Leire, Alegret, Montserrat, Ortega, Gemma, Espinosa, Ana, Sanabria, Ángela, Pérez-Cordón, Alba, Lleonart, Núria, Muñoz, Nathalia, Tárraga, Lluís, Ruiz, Agustín, and Boada, Mercè

Published
2022
Full Text
View/download PDF

4. Macular vessel density in the superficial plexus is not associated to cerebrovascular damage in non‐demented individuals: data from the NORFACE cohort

Author

Marquié, Marta, primary, García‐Sánchez, Ainhoa, additional, Sotolongo‐Grau, Oscar, additional, Tartari, Juan Pablo, additional, Sanabria, Angela, additional, Esteban‐De Antonio, Ester, additional, Pérez, Alba, additional, Castilla‐Martí, Miguel, additional, Castilla‐Martí, Luis, additional, Martínez, Joan, additional, Alarcón‐Martín, Emilio, additional, Alegret, Montserrat, additional, Aguilera, Núria, additional, Vivas, Assumpta, additional, M, Gómez‐Chiari, additional, Escudero, José Miguel, additional, Tejero, Miguel Angel, additional, Tárraga, Lluís, additional, Ruiz, Agustin, additional, and Boada, Mercè, additional

Published
2023
Full Text
View/download PDF

5. Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

Author

Valero, Sergi, Marquié, Marta, De Rojas, Itziar, Espinosa, Ana, Moreno-Grau, Sonia, Orellana, Adelina, Montrreal, Laura, Hernández, Isabel, Mauleón, Ana, Rosende-Roca, Maitée, Alegret, Montse, Pérez-Cordón, Alba, Ortega, Gemma, Roberto, Natalia, Sanabria, Angela, Abdelnour, Carla, Gil, Silvia, Tartari, Juan Pablo, Vargas, Liliana, Esteban-De Antonio, Ester, Benaque, Alba, Tárraga, Lluís, Boada, Mercè, and Ruíz, Agustín

Published
2020
Full Text
View/download PDF

6. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort

Author

Marquié, Marta, primary, García-Sánchez, Ainhoa, additional, Alarcón-Martín, Emilio, additional, Martínez, Joan, additional, Castilla-Martí, Miguel, additional, Castilla-Martí, Luis, additional, Orellana, Adelina, additional, Montrreal, Laura, additional, de Rojas, Itziar, additional, García-González, Pablo, additional, Puerta, Raquel, additional, Olivé, Clàudia, additional, Cano, Amanda, additional, Hernández, Isabel, additional, Rosende-Roca, Maitée, additional, Vargas, Liliana, additional, Tartari, Juan Pablo, additional, Esteban-De Antonio, Ester, additional, Bojaryn, Urszula, additional, Ricciardi, Mario, additional, Ariton, Diana M., additional, Pytel, Vanesa, additional, Alegret, Montserrat, additional, Ortega, Gemma, additional, Espinosa, Ana, additional, Pérez-Cordón, Alba, additional, Sanabria, Ángela, additional, Muñoz, Nathalia, additional, Lleonart, Núria, additional, Aguilera, Núria, additional, Tárraga, Lluís, additional, Valero, Sergi, additional, Ruiz, Agustín, additional, and Boada, Mercè, additional

Published
2023
Full Text
View/download PDF

7. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment

Author

Marquié, Marta, primary, García-Gutiérrez, Fernando, additional, Orellana, Adelina, additional, Montrreal, Laura, additional, de Rojas, Itziar, additional, García-González, Pablo, additional, Puerta, Raquel, additional, Olivé, Clàudia, additional, Cano, Amanda, additional, Hernández, Isabel, additional, Rosende-Roca, Maitée, additional, Vargas, Liliana, additional, Tartari, Juan Pablo, additional, Esteban-De Antonio, Ester, additional, Bojaryn, Urszula, additional, Ricciardi, Mario, additional, Ariton, Diana M., additional, Pytel, Vanesa, additional, Alegret, Montserrat, additional, Ortega, Gemma, additional, Espinosa, Ana, additional, Pérez-Cordón, Alba, additional, Sanabria, Ángela, additional, Muñoz, Nathalia, additional, Lleonart, Núria, additional, Aguilera, Núria, additional, García-Sánchez, Ainhoa, additional, Alarcón-Martín, Emilio, additional, Tárraga, Lluís, additional, Ruiz, Agustín, additional, Boada, Mercè, additional, and Valero, Sergi, additional

Published
2023
Full Text
View/download PDF

8. Extracellular vesicles, the emerging mirrors of brain physiopathology

Author

Cano, Amanda, primary, Ettcheto, Miren, additional, Bernuz, Mireia, additional, Puerta, Raquel, additional, Esteban de Antonio, Ester, additional, Sánchez-López, Elena, additional, Souto, Eliana B., additional, Camins, Antonio, additional, Martí, Mercè, additional, Pividori, María Isabel, additional, Boada, Mercè, additional, and Ruiz, Agustín, additional

Published
2023
Full Text
View/download PDF

9. Additional file 1 of Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

Author

Cano, Amanda, Esteban-de-Antonio, Ester, Bernuz, Mireia, Puerta, Raquel, García-González, Pablo, de Rojas, Itziar, Olivé, Claudia, Pérez-Cordón, Alba, Montrreal, Laura, Núñez-Llaves, Raúl, Sotolongo-Grau, Óscar, Alarcón-Martín, Emilio, Valero, Sergi, Alegret, Montserrat, Martín, Elvira, Martino-Adami, Pamela V., Ettcheto, Miren, Camins, Antonio, Vivas, Assumpta, Gomez-Chiari, Marta, Tejero, Miguel Ángel, Orellana, Adelina, Tárraga, Lluís, Marquié, Marta, Ramírez, Alfredo, Martí, Mercè, Pividori, María Isabel, Boada, Mercè, and Ruíz, Agustín

Abstract

Additional file 1: Figure S1. Neurology panel of Olink Proteomics (code 95801). Distribution of analytical measuring range, defined by the lower and upper limits of quantification (LLOQ-ULOQ), and normal plasma levels where data is available (dark blue bars) for 92 analytes. Figure S2. Inflammation panel of Olink Proteomics (code 95302). Distribution of analytical measuring range, defined by the limits of quantification LLOQ-ULOQ, for 90 out of 92 analytes. Table S1. List of proteins excluded/included in the study after the quality control analysis. Table S2. Demographics and biochemistry of the BIOFACE cohort. Table S3. Pearson correlations and effect between biomarkers in pEVs and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3. Table S4. Pearson correlations and effect between biomarkers in CSF and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3. Table S5. Pearson correlations and effect between biomarkers in plasma and most common parameters of AD analysis. Data ordered by R2. Displayed proteins above R2 > 0.3.

Published
2023
Full Text
View/download PDF

10. Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

Author

Orellana, Adelina, primary, García-González, Pablo, additional, Valero, Sergi, additional, Montrreal, Laura, additional, de Rojas, Itziar, additional, Hernández, Isabel, additional, Rosende-Roca, Maitee, additional, Vargas, Liliana, additional, Tartari, Juan Pablo, additional, Esteban-De Antonio, Ester, additional, Bojaryn, Urszula, additional, Narvaiza, Leire, additional, Alarcón-Martín, Emilio, additional, Alegret, Montserrat, additional, Alcolea, Daniel, additional, Lleó, Alberto, additional, Tárraga, Lluís, additional, Pytel, Vanesa, additional, Cano, Amanda, additional, Marquié, Marta, additional, Boada, Mercè, additional, and Ruiz, Agustín, additional

Published
2022
Full Text
View/download PDF

11. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer’s type

Author

Martino Adami, Pamela V, primary, Orellana, Adelina, additional, García, Pablo, additional, Kleineidam, Luca, additional, Alarcón-Martín, Emilio, additional, Montrreal, Laura, additional, Aguilera, Nuria, additional, Espinosa, Ana, additional, Abdelnour, Carla, additional, Rosende-Roca, Maitee, additional, Pablo Tartari, Juan, additional, Vargas, Liliana, additional, Mauleón, Ana, additional, Esteban-De Antonio, Ester, additional, López-Cuevas, Rogelio, additional, Dalmasso, Maria Carolina, additional, Campos Martin, Rafael, additional, Parveen, Kayenat, additional, Andrade Fuentes, Victor M, additional, Amin, Najaf, additional, Ahmad, Shahzad, additional, Ikram, M Arfan, additional, Lewczuk, Piotr, additional, Kornhuber, Johannes, additional, Peters, Oliver, additional, Frölich, Lutz, additional, Rüther, Eckart, additional, Wiltfang, Jens, additional, Tarraga, Lluis, additional, Boada, Merce, additional, Maier, Wolfgang, additional, de Rojas, Itziar, additional, Cano, Amanda, additional, Sanabria, Angela, additional, Alegret, Montserrat, additional, Hernández, Isabel, additional, Marquié, Marta, additional, Valero, Sergi, additional, van Duijn, Cornelia M, additional, Wagner, Michael, additional, Jessen, Frank, additional, Schneider, Anja, additional, Sáez Goñi, María Eugenia, additional, González Pérez, Antonio, additional, Ruiz, Agustín, additional, and Ramírez, Alfredo, additional

Published
2022
Full Text
View/download PDF

12. Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment

Author

Roberto, Natalia, primary, Portella, Maria J., additional, Marquié, Marta, additional, Alegret, Montserrat, additional, Hernández, Isabel, additional, Mauleón, Ana, additional, Rosende-Roca, Maitee, additional, Abdelnour, Carla, additional, Esteban de Antonio, Ester, additional, Tartari, Juan P., additional, Vargas, Liliana, additional, López-Cuevas, Rogelio, additional, Bojaryn, Urszula, additional, Espinosa, Ana, additional, Ortega, Gemma, additional, Pérez-Cordón, Alba, additional, Sanabria, Ángela, additional, Orellana, Adelina, additional, de Rojas, Itziar, additional, Moreno-Grau, Sonia, additional, Montrreal, Laura, additional, Alarcón-Martín, Emilio, additional, Ruíz, Agustín, additional, Tárraga, Lluís, additional, Boada, Mercè, additional, and Valero, Sergi, additional

Published
2021
Full Text
View/download PDF

13. Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The Fundació ACE Biomarker Research Program (FACEBREP)

Author

Orellana, Adelina, primary, Valero, Sergi, additional, Abdelnour, Carla, additional, Montrreal, Laura, additional, de Rojas, Itziar, additional, Rosende‐Roca, Maitee, additional, Mauleon, Ana, additional, Vargas, Liliana, additional, Tartari, Juan Pablo, additional, Esteban‐De Antonio, Ester, additional, García‐González, Pablo, additional, Alarcón‐Martín, Emilio, additional, Alegret, Montserrat, additional, Alcolea, Daniel, additional, Lleó, Alberto, additional, Hernandez, Isabel, additional, Tarraga, Lluis, additional, Marquié, Marta, additional, and Boada, Mercè, additional

Published
2021
Full Text
View/download PDF

16. BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols.

Author

Esteban de Antonio, Ester, Pérez-Cordón, Alba, Gil, Silvia, Orellana, Adelina, Cano, Amanda, Alegret, Montserrat, Espinosa, Ana, Alarcón-Martín, Emilio, Valero, Sergi, Martínez, Joan, de Rojas, Itziar, Sotolongo-Grau, Óscar, Martín, Elvira, Vivas, Assumpta, Gomez-Chiari, Marta, Tejero, Miguel Ángel, Bernuz, Mireia, Tárraga, Lluis, Ruiz, Agustín, and Marquié, Marta

Subjects
*MILD cognitive impairment, *PROGNOSIS, *ALZHEIMER'S disease, *LONGITUDINAL method, *BIOMARKERS, *RESEARCH, *RESEARCH methodology, *COGNITION, *MAGNETIC resonance imaging, *MEDICAL cooperation, *EVALUATION research, *NEUROPSYCHOLOGICAL tests, *COMPARATIVE studies, *PSYCHOLOGICAL tests
Abstract

Background: Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) diagnosis is based on cerebrospinal fluid (CSF) or neuroimaging biomarkers. Currently, non-invasive and inexpensive blood-based biomarkers are being investigated, such as neuronal-derived plasma exosomes (NPEs). Neuroinflammation and early vascular changes have been described in AD pathogenesis and can be traced in plasma and NPEs. However, they have not been studied in early onset MCI (EOMCI).Objective: To describe the rationale, design, and baseline characteristics of the participants from the BIOFACE cohort, a two-year observational study on EOMCI conducted at Fundació ACE. The study goal is to characterize the different phenotypes from a clinical, neuropsychological, and biomarker point of view and to investigate the CSF and plasma proteomics as well as the role of NPEs as early biomarkers of AD.Methods: Participants underwent extended neurological and neuropsychological batteries, multimodal biomarkers including brain MRI, blood, saliva, CSF, anthropometric, and neuro-ophthalmological examinations.Results: Ninety-seven patients with EOMCI were recruited. 59.8%were women. Mean age at symptom onset was 57 years; mean MMSE was 28. First degree and presenile family history of dementia was present in 60.8%and 15.5%, respectively. Depressive and anxiety disorders along with vascular risk factors were the most frequent comorbidities. 29%of participants were APOE ɛ4 carriers, and 67%showed a CSF normal ATN profile.Conclusion: BIOFACE is a two-year study of clinical, cognition, and biomarkers that will shed light on the physiopathology and the potential utility of plasma and NPEs as non-invasive early diagnostic and prognostic biomarkers in people younger than 65 years. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Managing Clinical Trials for Alzheimer's Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain.

Author

Abdelnour, Carla, Esteban de Antonio, Ester, Pérez-Cordón, Alba, Lafuente, Asunción, Buendía, Mar, Pancho, Ana, Jofresa, Sara, Aguilera, Nuria, Ibarria, Marta, Cuevas, Rosario, Cañada, Laia, Calvet, Anna, Diego, Susana, González-Pérez, Antonio, Orellana, Adela, Montrreal, Laura, de Jorge, Laura, Marquié, Marta, Benaque, Alba, and Gurruchaga, Miren

Subjects
*COVID-19 pandemic, *ALZHEIMER'S disease, *CLINICAL trials, *SERODIAGNOSIS, *SARS-CoV-2, *ALZHEIMER'S disease treatment, *PREVENTION of epidemics, *VIRAL pneumonia, *EXPERIMENTAL design, *CLINICAL pathology, *COVID-19, *MEDICAL care, *PATIENTS, *CLINICS, *TELEMEDICINE
Abstract

Background: The COVID-19 pandemic has brought great disruption to health systems worldwide. This affected ongoing clinical research, particularly among those most vulnerable to the pandemic, like dementia patients. Fundació ACE is a research center and memory clinic based in Barcelona, Spain, one of the hardest-hit countries.Objective: To describe the ad-hoc strategic plan developed to cope with this crisis and to share its outcomes.Methods: We describe participants' clinical and demographic features. Additionally, we explain our strategic plan aimed at minimizing the impact on clinical trial research activities, which included SARS-CoV-2 RT-PCR and IgG serological tests to all participants and personnel. The outcomes of the plan are described in terms of observed safety events and drop-outs during the study period.Results: A total of 130 patients were participating in 16 active clinical trials in Fundació ACE when the lockdown was established. During the confinement, we performed 1018 calls to the participants, which led to identify adverse events in 26 and COVID-19 symptoms in 6. A total of 83 patients (64%) could restart on-site visits as early as May 11, 2020. All SARS-CoV-2 RT-PCR diagnostic tests performed before on-site visits were negative and only three IgG serological tests were positive. Throughout the study period, we only observed one drop-out, due to an adverse event unrelated to COVID-19.Discussion: The plan implemented by Fundació ACE was able to preserve safety and integrity of ongoing clinical trials. We must use the lessons learned from the pandemic and design crisis-proof protocols for clinical trials. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.

Author

Marquié M, Valero S, Castilla-Marti M, Martínez J, Rodríguez-Gómez O, Sanabria Á, Tartari JP, Monté-Rubio GC, Sotolongo-Grau O, Alegret M, Pérez-Cordón A, Roberto N, de Rojas I, Moreno-Grau S, Montrreal L, Hernández I, Rosende-Roca M, Mauleón A, Vargas L, Abdelnour C, Gil S, Esteban-De Antonio E, Espinosa A, Ortega G, Lomeña F, Pavia J, Vivas A, Tejero MÁ, Gómez-Chiari M, Simó R, Ciudin A, Hernández C, Orellana A, Benaque A, Ruiz A, Tárraga L, and Boada M

Subjects
Aged, Brain diagnostic imaging, Brain metabolism, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Alzheimer Disease diagnosis, Amyloid beta-Peptides metabolism, Cognitive Dysfunction diagnostic imaging, Retina diagnostic imaging, Retina pathology
Abstract

Background: Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake., Aims: We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD., Methods: One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/-) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2., Results: Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02-1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months., Conclusions: Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results